Sit Investment Associates Inc. decreased its position in shares of Allergan PLC (NYSE:AGN) by 3.0% during the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 36,130 shares of the company’s stock after selling 1,100 shares during the period. Sit Investment Associates Inc.’s holdings in Allergan PLC were worth $8,349,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently modified their holdings of the company. Barnett & Company Inc. purchased a new position in shares of Allergan PLC during the first quarter worth about $111,000. Livingston Group Asset Management CO operating as Southport Capital Management purchased a new position in shares of Allergan PLC during the second quarter worth about $125,000. Trust Co. of Vermont boosted its position in shares of Allergan PLC by 19.5% in the second quarter. Trust Co. of Vermont now owns 545 shares of the company’s stock worth $126,000 after buying an additional 89 shares in the last quarter. Ropes Wealth Advisors LLC boosted its position in shares of Allergan PLC by 13.2% in the first quarter. Ropes Wealth Advisors LLC now owns 497 shares of the company’s stock worth $133,000 after buying an additional 58 shares in the last quarter. Finally, Integrated Investment Consultants LLC boosted its position in shares of Allergan PLC by 35.2% in the second quarter. Integrated Investment Consultants LLC now owns 592 shares of the company’s stock worth $137,000 after buying an additional 154 shares in the last quarter. Hedge funds and other institutional investors own 85.19% of the company’s stock.
Allergan PLC (NYSE:AGN) traded up 0.54% during trading on Thursday, hitting $236.98. 1,917,009 shares of the company traded hands. Allergan PLC has a 12-month low of $195.50 and a 12-month high of $322.68. The company has a market capitalization of $93.83 billion, a P/E ratio of 22.56 and a beta of 0.81. The stock has a 50 day moving average price of $240.82 and a 200 day moving average price of $239.60.
Allergan PLC (NYSE:AGN) last issued its quarterly earnings data on Monday, August 8th. The company reported $3.35 earnings per share for the quarter, beating the consensus estimate of $3.34 by $0.01. Allergan PLC had a return on equity of 7.67% and a net margin of 28.06%. The business had revenue of $3.68 billion for the quarter, compared to analysts’ expectations of $4.10 billion. During the same period last year, the business earned $4.41 EPS. The business’s revenue was up 1.0% on a year-over-year basis. On average, equities analysts anticipate that Allergan PLC will post $14.00 earnings per share for the current year.
AGN has been the subject of a number of analyst reports. Zacks Investment Research upgraded shares of Allergan PLC from a “hold” rating to a “buy” rating and set a $274.00 price objective for the company in a report on Friday, July 15th. Vetr cut shares of Allergan PLC from a “strong-buy” rating to a “buy” rating and set a $272.10 price objective for the company. in a report on Thursday, July 14th. Bank of America Corp. reiterated a “buy” rating and issued a $294.00 price target (up previously from $287.00) on shares of Allergan PLC in a report on Wednesday, June 29th. Goldman Sachs Group Inc. reiterated a “buy” rating on shares of Allergan PLC in a report on Wednesday, July 6th. Finally, Leerink Swann reiterated a “buy” rating on shares of Allergan PLC in a report on Thursday, June 30th. Six research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $302.52.
Allergan PLC Company Profile
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC (NYSE:AGN).
Receive News & Ratings for Allergan PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC and related companies with MarketBeat.com's FREE daily email newsletter.